Aegis Therapeutics has announced the availability of “an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug.” Aegis’s intranasal product would be the only non-injectable formulation of exenatide, a GLP-1 analog that is currently marketed as Byetta and Bydureon by AstraZeneca.
The intranasal formulation uses Aegis’s Intravail transmucosal absorption enhancer. Aegis recently announced that it had received a US patent for a stable formulation of intranasal insulin using the Intravail technology along with the company’s ProTek protein stabilization excipients.
Read the Aegis press release.
